Shaobin Ni
- Urology top 5%
-
- Cancer, Hypoxia, and Metabolism 5
- Cancer, Lipids, and Metabolism 3
- MicroRNA in disease regulation 2
-
- Kidney Stones and Urolithiasis Treatments 5
- Renal cell carcinoma treatment 3
-
- Pediatric Urology and Nephrology Studies 6
-
- Bladder and Urothelial Cancer Treatments 5
-
- Dialysis and Renal Disease Management 2
- Partner nations
- ChinaUnited States
In The Last Decade
Shaobin Ni
22 papers receiving 592 citations
Peers
Comparison fields: 5 of 79
- Urology 71
- Cancer Research 145
- Pulmonary and Respiratory Medicine 204
- Pediatrics, Perinatology and Child Health 95
- Surgery 205
Countries citing papers authored by Shaobin Ni
This map shows the geographic impact of Shaobin Ni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shaobin Ni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shaobin Ni more than expected).
Fields of papers citing papers by Shaobin Ni
This network shows the impact of papers produced by Shaobin Ni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shaobin Ni. The network helps show where Shaobin Ni may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Shaobin Ni, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 1 | |
| 2 | 2021 | 2 | |
| 3 | 2021 | 34 | |
| 4 | 2020 | 17 | |
| 5 | 2019 | 2 | |
| 6 | 2019 | 13 | |
| 7 | 2016 | 42 | |
| 8 | 2015 | 6 | |
| 9 | 2015 | 32 | |
| 10 | 2015 | 45 | |
| 11 | 2014 | 8 | |
| 12 | 2014 | 85 | |
| 13 | 2014 | 37 | |
| 14 | 2013 | 65 | |
| 15 | Antitumor effects of mutant endostatin are enhanced by Bcl-2 antisense oligonucleotides in UM-UC-3 bladder cancer cell line. | 2013 | 2 |
| 16 | 2012 | 130 | |
| 17 | 2011 | 46 | |
| 18 | 2010 | 16 | |
| 19 | 2009 | 2 | |
| 20 | [Treatment of ureteral obstruction by holmium: YAG laser endoureterotomy: a report of 18 cases]. | 2009 | 5 |
About Shaobin Ni
Shaobin Ni is a scholar working on Cancer Research, Pediatrics, Perinatology and Child Health, Nephrology, Pulmonary and Respiratory Medicine and Obstetrics and Gynecology, having authored 22 papers that have together received 603 indexed citations. Recurring topics across this work include Pediatric Urology and Nephrology Studies (6 papers), Cancer, Hypoxia, and Metabolism (5 papers), Bladder and Urothelial Cancer Treatments (5 papers), Kidney Stones and Urolithiasis Treatments (5 papers), Renal cell carcinoma treatment (3 papers), Cancer, Lipids, and Metabolism (3 papers), MicroRNA in disease regulation (2 papers) and Dialysis and Renal Disease Management (2 papers). The work is most often cited by research in Urology (71 citations), Cancer Research (145 citations), Pulmonary and Respiratory Medicine (204 citations), Pediatrics, Perinatology and Child Health (95 citations) and Surgery (205 citations). Shaobin Ni has collaborated with scholars based in China and United States. Frequent co-authors include Qi-Yin Chen, Weiyang Tao, Chunyang Wang, Ruifa Han, Hongchi Jiang, Hailong Hu, Lianxin Liu, Chunyang Wang, Tong Ren and Dali Zhao. Their work appears in journals such as Urology, Cancer Science, PLoS ONE, Cell Biology International and Chinese Journal of Integrative Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.